vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and PROVIDENT FINANCIAL SERVICES INC (PFS). Click either name above to swap in a different company.

PROVIDENT FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($225.2M vs $154.2M, roughly 1.5× BridgeBio Pharma, Inc.). PROVIDENT FINANCIAL SERVICES INC runs the higher net margin — 35.3% vs -126.2%, a 161.5% gap on every dollar of revenue.

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

BBIO vs PFS — Head-to-Head

Bigger by revenue
PFS
PFS
1.5× larger
PFS
$225.2M
$154.2M
BBIO
Higher net margin
PFS
PFS
161.5% more per $
PFS
35.3%
-126.2%
BBIO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BBIO
BBIO
PFS
PFS
Revenue
$154.2M
$225.2M
Net Profit
$-194.6M
$79.4M
Gross Margin
94.7%
Operating Margin
-90.5%
Net Margin
-126.2%
35.3%
Revenue YoY
2521.2%
Net Profit YoY
27.2%
24.0%
EPS (diluted)
$-1.00
$0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
PFS
PFS
Q1 26
$225.2M
Q4 25
$154.2M
$225.7M
Q3 25
$120.7M
$221.8M
Q2 25
$110.6M
$214.2M
Q1 25
$116.6M
$208.8M
Q4 24
$205.9M
Q3 24
$210.6M
Q2 24
$163.8M
Net Profit
BBIO
BBIO
PFS
PFS
Q1 26
$79.4M
Q4 25
$-194.6M
Q3 25
$-184.9M
$71.7M
Q2 25
$-183.8M
$72.0M
Q1 25
$-169.6M
$64.0M
Q4 24
Q3 24
$46.4M
Q2 24
$-11.5M
Gross Margin
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
94.7%
Q3 25
94.6%
Q2 25
96.7%
Q1 25
97.7%
Q4 24
Q3 24
Q2 24
Operating Margin
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
-90.5%
49.7%
Q3 25
-120.3%
45.8%
Q2 25
-121.4%
47.8%
Q1 25
-89.5%
44.0%
Q4 24
30.5%
Q3 24
31.0%
Q2 24
-13.0%
Net Margin
BBIO
BBIO
PFS
PFS
Q1 26
35.3%
Q4 25
-126.2%
Q3 25
-153.2%
32.3%
Q2 25
-166.2%
33.6%
Q1 25
-145.4%
30.7%
Q4 24
Q3 24
22.0%
Q2 24
-7.0%
EPS (diluted)
BBIO
BBIO
PFS
PFS
Q1 26
$0.61
Q4 25
$-1.00
$0.64
Q3 25
$-0.95
$0.55
Q2 25
$-0.95
$0.55
Q1 25
$-0.88
$0.49
Q4 24
$0.37
Q3 24
$0.36
Q2 24
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
PFS
PFS
Cash + ST InvestmentsLiquidity on hand
$570.1M
$222.1M
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$-2.1B
$2.9B
Total Assets
$936.0M
$25.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
PFS
PFS
Q1 26
$222.1M
Q4 25
$570.1M
$209.1M
Q3 25
$643.0M
$299.2M
Q2 25
$756.9M
$258.0M
Q1 25
$540.6M
$234.1M
Q4 24
$205.9M
Q3 24
$244.0M
Q2 24
$290.5M
Total Debt
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
$2.0B
Q3 25
$2.0B
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BBIO
BBIO
PFS
PFS
Q1 26
$2.9B
Q4 25
$-2.1B
$2.8B
Q3 25
$-1.9B
$2.8B
Q2 25
$-1.8B
$2.7B
Q1 25
$-1.6B
$2.7B
Q4 24
$2.6B
Q3 24
$2.6B
Q2 24
$2.6B
Total Assets
BBIO
BBIO
PFS
PFS
Q1 26
$25.2B
Q4 25
$936.0M
$25.0B
Q3 25
$998.3M
$24.8B
Q2 25
$1.1B
$24.5B
Q1 25
$881.6M
$24.2B
Q4 24
$24.1B
Q3 24
$24.0B
Q2 24
$24.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
PFS
PFS
Operating Cash FlowLast quarter
$-56.4M
Free Cash FlowOCF − Capex
$-56.5M
FCF MarginFCF / Revenue
-36.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
$-56.4M
$442.3M
Q3 25
$-109.6M
$98.0M
Q2 25
$-80.7M
$186.8M
Q1 25
$-199.2M
$88.5M
Q4 24
$426.4M
Q3 24
$69.2M
Q2 24
$76.5M
Free Cash Flow
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
$-56.5M
$430.7M
Q3 25
$-110.0M
$96.7M
Q2 25
$-81.3M
$182.6M
Q1 25
$87.4M
Q4 24
$425.1M
Q3 24
$67.9M
Q2 24
$75.5M
FCF Margin
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
-36.6%
190.8%
Q3 25
-91.2%
43.6%
Q2 25
-73.5%
85.2%
Q1 25
41.9%
Q4 24
206.4%
Q3 24
32.2%
Q2 24
46.1%
Capex Intensity
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
0.0%
5.1%
Q3 25
0.4%
0.6%
Q2 25
0.5%
2.0%
Q1 25
0.0%
0.5%
Q4 24
0.6%
Q3 24
0.6%
Q2 24
0.6%
Cash Conversion
BBIO
BBIO
PFS
PFS
Q1 26
Q4 25
Q3 25
1.37×
Q2 25
2.59×
Q1 25
1.38×
Q4 24
Q3 24
1.49×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBIO
BBIO

Segment breakdown not available.

PFS
PFS

Net Interest Income$193.7M86%
Noninterest Income$31.5M14%

Related Comparisons